Free Trial
NASDAQ:VTGN

VistaGen Therapeutics (VTGN) Stock Price, News & Analysis

VistaGen Therapeutics logo
$2.73 -0.24 (-8.08%)
Closing price 08/7/2025 04:00 PM Eastern
Extended Trading
$2.77 +0.04 (+1.47%)
As of 08/7/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About VistaGen Therapeutics Stock (NASDAQ:VTGN)

Key Stats

Today's Range
$2.71
$3.00
50-Day Range
$1.96
$3.19
52-Week Range
$1.90
$3.79
Volume
507,513 shs
Average Volume
402,302 shs
Market Capitalization
$81.52 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Buy

Company Overview

VistaGen Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
20th Percentile Overall Score

VTGN MarketRank™: 

VistaGen Therapeutics scored higher than 20% of companies evaluated by MarketBeat, and ranked 842nd out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Earnings Growth

    Earnings for VistaGen Therapeutics are expected to grow in the coming year, from ($1.77) to ($1.74) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of VistaGen Therapeutics is -1.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of VistaGen Therapeutics is -1.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    VistaGen Therapeutics has a P/B Ratio of 1.12. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about VistaGen Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    1.91% of the float of VistaGen Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    VistaGen Therapeutics has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in VistaGen Therapeutics has recently decreased by 89.13%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    VistaGen Therapeutics does not currently pay a dividend.

  • Dividend Growth

    VistaGen Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.91% of the float of VistaGen Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    VistaGen Therapeutics has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in VistaGen Therapeutics has recently decreased by 89.13%, indicating that investor sentiment is improving significantly.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for VistaGen Therapeutics this week, compared to 1 article on an average week.
  • Search Interest

    6 people have searched for VTGN on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added VistaGen Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, VistaGen Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 2.85% of the stock of VistaGen Therapeutics is held by insiders.

  • Percentage Held by Institutions

    78.39% of the stock of VistaGen Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about VistaGen Therapeutics' insider trading history.
Receive VTGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for VistaGen Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

VTGN Stock News Headlines

Elon’s BIGGEST warning yet?
Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.
VistaGen Therapeutics Q1 2026 Earnings Preview
See More Headlines

VTGN Stock Analysis - Frequently Asked Questions

VistaGen Therapeutics' stock was trading at $2.95 at the beginning of 2025. Since then, VTGN shares have decreased by 7.5% and is now trading at $2.73.

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) issued its quarterly earnings data on Thursday, August, 7th. The company reported ($0.47) earnings per share for the quarter, missing analysts' consensus estimates of ($0.46) by $0.01. VistaGen Therapeutics had a negative trailing twelve-month return on equity of 58.88% and a negative net margin of 6,777.08%.
Read the conference call transcript
.

VistaGen Therapeutics's stock reverse split on the morning of Wednesday, June 7th 2023.The 1-30 reverse split was announced on Wednesday, June 7th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, June 7th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Top institutional investors of VistaGen Therapeutics include AdvisorShares Investments LLC (0.68%), Blair William & Co. IL (0.29%) and Simplex Trading LLC. Insiders that own company stock include Commodore Capital Lp, Shawn Singh, Reid G Adler and Jerry B Gin.
View institutional ownership trends
.

Shares of VTGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that VistaGen Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), CrowdStrike (CRWD), Adobe (ADBE), Advanced Micro Devices (AMD) and Arista Networks (ANET).

Company Calendar

Today
8/07/2025
Last Earnings
8/07/2025
Next Earnings (Estimated)
8/07/2025
Fiscal Year End
3/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:VTGN
CIK
1411685
Employees
40
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($1.66)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$51.42 million
Net Margins
-6,777.08%
Pretax Margin
-10,578.40%
Return on Equity
-58.88%
Return on Assets
-52.38%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
6.51
Quick Ratio
6.51

Sales & Book Value

Annual Sales
$490 thousand
Price / Sales
166.36
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.44 per share
Price / Book
1.12

Miscellaneous

Outstanding Shares
29,860,000
Free Float
29,009,000
Market Cap
$81.52 million
Optionable
Optionable
Beta
0.40

Social Links

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

This page (NASDAQ:VTGN) was last updated on 8/8/2025 by MarketBeat.com Staff
From Our Partners